Opinion
Video
Switching Between BTK Inhibitors in CLL
Author(s):
Panelists discuss how decisions to switch between Bruton tyrosine kinase (BTK) inhibitors are driven by multiple factors including intolerable toxicities, development of resistance mutations, disease progression, drug interactions, and patient preferences, with pirtobrutinib emerging as a particularly valuable option for patients with BTK C481 mutations or those who have exhausted other BTK inhibitor (BTKi) options.
Video content above is prompted by the following:
- What factors typically drive decisions to switch between BTK inhibitors: managing toxicity, addressing disease progression, or other considerations?
- How do these factors influence your decision on which therapy to switch to, either within the BTKi class or outside of it? Where does pirtobrutinib fit into this decision?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Videos
Related Content
